Literature DB >> 25364528

Chinese expert consensus on molecularly targeted therapy for advanced non-small cell lung cancer (2013 edition).

Guoming Wu1, Caicun Zhou1, Chunxue Bai1, Guisheng Qian1.   

Abstract

Entities:  

Year:  2014        PMID： 25364528      PMCID： PMC4215143          DOI： 10.3978/j.issn.2072-1439.2014.09.20

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  32 in total

1.  Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.

Authors:  Yi-Long Wu; Wen-Zhao Zhong; Long-Yun Li; Xiao-Tong Zhang; Li Zhang; Cai-Cun Zhou; Wei Liu; Bin Jiang; Xin-Lin Mu; Jia-Ying Lin; Qing Zhou; Chong-Rui Xu; Zhen Wang; Guo-Chun Zhang; Tony Mok
Journal:  J Thorac Oncol       Date:  2007-05       Impact factor: 15.609

2.  Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  S Peters; A A Adjei; C Gridelli; M Reck; K Kerr; E Felip
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

3.  ROS1 rearrangements define a unique molecular class of lung cancers.

Authors:  Kristin Bergethon; Alice T Shaw; Sai-Hong Ignatius Ou; Ryohei Katayama; Christine M Lovly; Nerina T McDonald; Pierre P Massion; Christina Siwak-Tapp; Adriana Gonzalez; Rong Fang; Eugene J Mark; Julie M Batten; Haiquan Chen; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; David P Carbone; Hongbin Ji; Jeffrey A Engelman; Mari Mino-Kenudson; William Pao; A John Iafrate
Journal:  J Clin Oncol       Date:  2012-01-03       Impact factor: 44.544

4.  Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

Authors:  Makoto Maemondo; Akira Inoue; Kunihiko Kobayashi; Shunichi Sugawara; Satoshi Oizumi; Hiroshi Isobe; Akihiko Gemma; Masao Harada; Hirohisa Yoshizawa; Ichiro Kinoshita; Yuka Fujita; Shoji Okinaga; Haruto Hirano; Kozo Yoshimori; Toshiyuki Harada; Takashi Ogura; Masahiro Ando; Hitoshi Miyazawa; Tomoaki Tanaka; Yasuo Saijo; Koichi Hagiwara; Satoshi Morita; Toshihiro Nukiwa
Journal:  N Engl J Med       Date:  2010-06-24       Impact factor: 91.245

5.  Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial.

Authors:  Marina Chiara Garassino; Olga Martelli; Massimo Broggini; Gabriella Farina; Silvio Veronese; Eliana Rulli; Filippo Bianchi; Anna Bettini; Flavia Longo; Luca Moscetti; Maurizio Tomirotti; Mirko Marabese; Monica Ganzinelli; Calogero Lauricella; Roberto Labianca; Irene Floriani; Giuseppe Giaccone; Valter Torri; Alberto Scanni; Silvia Marsoni
Journal:  Lancet Oncol       Date:  2013-07-22       Impact factor: 41.316

6.  Chemotherapy with Erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors.

Authors:  Sarah B Goldberg; Geoffrey R Oxnard; Subba Digumarthy; Alona Muzikansky; David M Jackman; Inga T Lennes; Lecia V Sequist
Journal:  Oncologist       Date:  2013-09-26

7.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

8.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

9.  Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Authors:  Yi-Long Wu; Jin Soo Lee; Sumitra Thongprasert; Chong-Jen Yu; Li Zhang; Guia Ladrera; Vichien Srimuninnimit; Virote Sriuranpong; Jennifer Sandoval-Tan; Yunzhong Zhu; Meilin Liao; Caicun Zhou; Hongming Pan; Victor Lee; Yuh-Min Chen; Yan Sun; Benjamin Margono; Fatima Fuerte; Gee-Chen Chang; Kasan Seetalarom; Jie Wang; Ashley Cheng; Elisna Syahruddin; Xiaoping Qian; James Ho; Johan Kurnianda; Hsingjin Eugene Liu; Kate Jin; Matt Truman; Ilze Bara; Tony Mok
Journal:  Lancet Oncol       Date:  2013-06-17       Impact factor: 41.316

10.  First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.

Authors:  Siow Ming Lee; Iftekhar Khan; Sunil Upadhyay; Conrad Lewanski; Stephen Falk; Geraldine Skailes; Ernie Marshall; Penella J Woll; Matthew Hatton; Rohit Lal; Richard Jones; Elizabeth Toy; David Chao; Gary Middleton; Sue Bulley; Yenting Ngai; Robin Rudd; Allan Hackshaw; Chris Boshoff
Journal:  Lancet Oncol       Date:  2012-10-16       Impact factor: 41.316
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.